IN23-01

Main Content

Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis

Study #: IN23-01

Study Status: Published

Presentation(s)

2025, ASH (Oral)

2026, Tandem (Poster)

Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR analysis.

Citation

Wudhikarn K, Gowda L, Ye Q, Oloyede T, Martens M, Banerjee R, Devarakonda SS, Liu H, Herr MM, Young JH, Jain T, Dias A, 13. Nishihori T, Mirza AS, Ganguly S, Beitinjaneh AM, Aljurf M, Wirk B, Farhadfar N, Efebera YA, Perales MA, Ebens CL, Murthy HS, Hill JA, Dandoy CE, Hong S, Boghdadly ZE, 28. Akhtar OS, Auletta JJ, Huppler AR, Abid MB.

Transplantation and Cellular Therapy. 2026, Jun 27: S2666-6367(26): S2666-6367(26):00497. doi: 10.1016/j.jtct.2026.06.029. Epub 2026, Jun 27. PMCID:.

PubMed

PMID: 42364732

Abstract